Global Reach
LIG-IAGIM
Drug Development Association signed close to a 190 generic drug
development projects in the 4Q of 2013 and 1Q -3Q of 2014 with generic
and innovative drug houses as diverse and far apart as Argentina,
Brazil, Canada, China, Denmark, Egypt, France, Germany, Jordan Iran,
Ireland, Malta, Malaysia, Mexico, Saudi Arabia, Singapore, South
Africa, UK, US and New Zealand.
LocumGroup now fully operational paperless back-office contributed
significantly to the rapid and smooth high speed technology transfer
process and proved itself to be a winner in cost effective IT process
management. As a global print and electronic Journal, Handbook and
technology publisher Locum's Paperless e-Office Systems developed
and validated over the past five years include rapid and effective
auto-invoicing, and client auto-banking to auto-shipping, goods
tracking and notification. Included in the paperless e-Office are
automatic tax e-filing and staff remuneration, e-insurance, e-pension,
e-autobanking, e-salary and e-filing features fully integrated from
Locum's Cape Town to Miami operations.
Technology
Leading
Generic and Innovative Drug Manufacturers purchased formulation
and development, scale-up, validation and commercial IT data, including
CMC and Analytical methodology and Bioavailability data profiles
from LIG- IAGIM Drug Development Association on an expanding worldwide
basis. An interesting development was China's new emergence in purchasing
original drug development know-how by non-state limited liability
pharma companies such as Hainan Poly Pharm.
Drug Development
Indian
pharma companies have extended and advanced their large drug development
product pipeline by purchasing LIG-IAGIM technology dosage form
specific handbooks and technical know-how. USV (India). Incepta
Bangladesh FamyCare (India) and Randbaxy (India) Wockhardt, Jubilant
Organosys (India), Microlabs (India), Tablets India and Ind-Swift
have acquired LIG-IAGIM Research and Development technological handbooks
and analytical methodology databases covering pre-formulation to
scale-up, and commercial manufacturing utilizing IAGIM extended
drug development benefit plus plans ranging from periods of 5 -8-
10 years for generic and innovative drug development.
Europe and ME
Product
development data in the Middle East region covered critical aspects
from formulation technology to large scale development plans. Egypt
(Amriya), Jordan (Advance Pharmaceuticals), Iran and Saudi Arabia
Jazeera Pharmaceutical Industries manufacturing complex have expanded
their modern manufacturing and development facilities. Locum International
technology including validated full scale commercial batches in
all the proposed marketing strengths enabling companies to slash
their generic pipeline queue from 10 -15 months of time saved when
compared to formulating from scratch. Locum's advanced modern IT
transfer technology reached as far as Lambo (Belgium), Bedi and
Fournier France, Alpharma (Denmark), CryoPharma SA (Mexico), KRKA
Slovenia, Indonesia's Sanbe Farma (Bandung), Dr Esteces (Spain)
Standard Chem and Pharm (Taiwan) and on to eastern Europe via Ukraine's
Hexal operations in Kiev.
Workshops and Drug Development Expositions
[US EXPO]
IAGIM
continued to advance and spread it's state-of-the-art drug development
know-how and validated commercial sized manufacturing technology
to the four corners of the earth in approximately 110 countries.
A new development was highlighted in the P.R. of China (PolyPharm)
incorporating additional western high tech based technology and
guidelines. IAGIM conducted regular drug development formulation
seminars symposia and workshops in all five continents. The annual
CT and US drug development Exposition (CT, US EXPO) drew in large
interested clientele from every continent, as well as major generic
and innovative drug development companies, research laboratories
and big pharma consultants.
Asia Technology
India
has maintained its' status and lead as a major technology purchaser
of LIG-IAGIM information technology (IT) and drug development know-how
covering all aspects from A-Z of Locum's databases.
Major Indian drug houses such as Adjunta, Centaur Pharmaceutical,
CadilaPharm, GlaxoSmithKline (Philippines), Indoco, IPCA, JB Chemicals
and Pharmaceuticals, RatioPharm, Orchid, Cipla, Novartis, Nicholas
Piramal, Randbaxy, Strides Arcolabs, Sun Pharma, USV, Wockhardt
and Dr. Reddys have expanded their state-of-the-art international
level operations and advanced research, development and manufacturing
capabilities utilizing key aspects of Locum International Group's
generic and innovative drug development, HPLC + UV validated analytical
methodology, development e-SOP and FDA and EU level commercial manufacturing
technology to their product export advantage.
Global Technology
Locum
International Research Ltd., is headquarters in Israel, Locum International
Inc. in Florida USA and Locum International Group Switzerland. The
Group is among the top pharmaceutical generic pharmaceutical drug
development company in the world. The company researches and develops
generic formulations, manufacturing processes, scale-up and validation
commercial sized procedures and markets generic and innovative controlled
release and sterile pharmaceuticals as well as active pharmaceutical
ingredients know-how and technology, such as the neurobiological
innovative drugs (F-CRAB's, CMZ CR) worldwide in over a 175+ countries.
LIG provides and presents leading FDA and EU approved SOPs, PAIs,
analytical methods, ANDAs, dossiers, seminars, workshops and conferences
worldwide, covering both pharmaceutical and neurobiology (F-CRAB's).
Neurobiological Development - F-CRAB's
/ CMZ CR
LI neurobiology development and experimental unit is currently developing
advanced default protein folding mechanisms and routes for the F-CRAB
RRMS drugs (relapsing remitting multiple sclerosis family of drugs),
which include the development of the second generation Glatiramer
Acetate Copoxane2 (COP2),
with special reference to the molecular weight spectrum (Av.25+nK
daltons spread and limits/10+nK->25+nK) of the truncated four
amino-acid glatiramer acetate complex, which has a significant batch-2-batch
(B2B-SV+RSD) synthesis variation, requiring advanced cGMP and QA/QC
controls, that differ significantly from the normal drug synthesis
pathways, especially in intermediate QA testing of the protected
intermediates. Impeccable cleaning validation, stringent controls
of starting, intermediate raw materials and solvents, resulting
in significantly tighter batch to batch variations and B2B RSD's
and impurity profiles, using special HPLC column and gel-filtration
analytical methodology techniques.
Innovative Research
Workshops, lectures and seminars on the F-CRAB RRMS drugs, their
development, synthesis, formulation, proposed default 'protein'
folding, HPLC / gel filtration analysis/A.M validation and associated
e-CTD/CTD specification / parameters are available as per advertised
timetable in both EU and the US journal series (Contact LIG). The
International Journal of Drug Development (IJDD Vol. 10/11) and
the International Journal of Drug R&D (IJDR&D Vol. 11/12)
are the main current print venues in the International Journal Series
for publishing the ongoing F-CRAB RRMS drug innovation, experimental
research and product development. Other venues include International
Journal of Drug cGMP (IJGMP) and International Journal of Drug Validation
(IJDV) and International Journal of Drug Master Formula and Processes
(IJDM&P).
Market Highlights
Over
85% of Locum's technology sales are in Asia/China/Japan (39), North
America (31) and Europe (30).
For additional information contact LIGroup (www.LocumUSA.com) or
IAGIM (www.iagim.org) or use the LIG international tel/voice
messaging system US +1-561-865-6147
Pharma
Today, International Journal of Generic Drugs, Times of India, Mail
and
Guardian Washington Post and Times
|